These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

195 related items for PubMed ID: 21330050

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Combined gene expression profiling and RNAi screening in clear cell renal cell carcinoma identify PLK1 and other therapeutic kinase targets.
    Ding Y, Huang D, Zhang Z, Smith J, Petillo D, Looyenga BD, Feenstra K, Mackeigan JP, Furge KA, Teh BT.
    Cancer Res; 2011 Aug 01; 71(15):5225-34. PubMed ID: 21642374
    [Abstract] [Full Text] [Related]

  • 4. Overexpression of polo-like kinase 1 and its clinical significance in human non-small cell lung cancer.
    Wang ZX, Xue D, Liu ZL, Lu BB, Bian HB, Pan X, Yin YM.
    Int J Biochem Cell Biol; 2012 Jan 01; 44(1):200-10. PubMed ID: 22064247
    [Abstract] [Full Text] [Related]

  • 5. [Effect of antisense RNA targeting Polo-like kinase 1 on cell cycle of lung cancer cell line A549].
    Zhou Q, Bai M, Su Y.
    Ai Zheng; 2005 Feb 01; 24(2):149-54. PubMed ID: 15694023
    [Abstract] [Full Text] [Related]

  • 6. [Study of growth inhibition of gastric cancer cells by sRNA targeting polo like kinase 1 in vitro and vivo].
    Lan B, Liu BY, Cheng XH, Qu Y, Zhang XQ, Cai Q, Dai QB, Zhu ZG.
    Zhonghua Wai Ke Za Zhi; 2006 Jan 01; 44(1):40-4. PubMed ID: 16620646
    [Abstract] [Full Text] [Related]

  • 7. Aberrant Polo-like kinase 1-Cdc25A pathway in metastatic hepatocellular carcinoma.
    Wang XQ, Zhu YQ, Lui KS, Cai Q, Lu P, Poon RT.
    Clin Cancer Res; 2008 Nov 01; 14(21):6813-20. PubMed ID: 18980975
    [Abstract] [Full Text] [Related]

  • 8. Small interfering RNA-mediated Polo-like kinase 1 depletion preferentially reduces the survival of p53-defective, oncogenic transformed cells and inhibits tumor growth in animals.
    Guan R, Tapang P, Leverson JD, Albert D, Giranda VL, Luo Y.
    Cancer Res; 2005 Apr 01; 65(7):2698-704. PubMed ID: 15805268
    [Abstract] [Full Text] [Related]

  • 9. Silencing of polo-like kinase (Plk) 1 via siRNA causes induction of apoptosis and impairment of mitosis machinery in human prostate cancer cells: implications for the treatment of prostate cancer.
    Reagan-Shaw S, Ahmad N.
    FASEB J; 2005 Apr 01; 19(6):611-3. PubMed ID: 15661849
    [Abstract] [Full Text] [Related]

  • 10. Silencing of polo-like kinase (Plk) 1 via siRNA causes inhibition of growth and induction of apoptosis in human esophageal cancer cells.
    Bu Y, Yang Z, Li Q, Song F.
    Oncology; 2008 Apr 01; 74(3-4):198-206. PubMed ID: 18714168
    [Abstract] [Full Text] [Related]

  • 11. [Mitosis arrest caused by inhibition of PLK1 expression in gastric cancer MKN45 cells].
    Lan B, Liu BY, Chen XH, Qu Y, Zhang XQ, Cai Q, Dai QB, Zhu ZG.
    Zhonghua Zhong Liu Za Zhi; 2006 Mar 01; 28(3):164-8. PubMed ID: 16875597
    [Abstract] [Full Text] [Related]

  • 12. Downregulation of human polo-like kinase activity by antisense oligonucleotides induces growth inhibition in cancer cells.
    Spänkuch-Schmitt B, Wolf G, Solbach C, Loibl S, Knecht R, Stegmüller M, von Minckwitz G, Kaufmann M, Strebhardt K.
    Oncogene; 2002 May 09; 21(20):3162-71. PubMed ID: 12082631
    [Abstract] [Full Text] [Related]

  • 13. Polo-like Kinase 1-targeting Chitosan Nanoparticles Suppress the Progression of Hepatocellular Carcinoma.
    Wang D, Chang R, Wang G, Hu B, Qiang Y, Chen Z.
    Anticancer Agents Med Chem; 2017 May 09; 17(7):948-954. PubMed ID: 27671301
    [Abstract] [Full Text] [Related]

  • 14. [Expression and prognostic value of Polo-like kinase 1, E-cadherin in the patients with hepatocellular carcinoma].
    Chen XJ, Wu LM, Xu XB, Feng XW, Xie HY, Zhang M, Shen Y, Wang WL, Liang TB, Zheng SS.
    Zhonghua Wai Ke Za Zhi; 2007 Oct 01; 45(19):1354-8. PubMed ID: 18241575
    [Abstract] [Full Text] [Related]

  • 15. Down-regulation of Polo-like kinase 1 elevates drug sensitivity of breast cancer cells in vitro and in vivo.
    Spänkuch B, Heim S, Kurunci-Csacsko E, Lindenau C, Yuan J, Kaufmann M, Strebhardt K.
    Cancer Res; 2006 Jun 01; 66(11):5836-46. PubMed ID: 16740723
    [Abstract] [Full Text] [Related]

  • 16. Polo-like kinase 1 is a therapeutic target in high-risk neuroblastoma.
    Ackermann S, Goeser F, Schulte JH, Schramm A, Ehemann V, Hero B, Eggert A, Berthold F, Fischer M.
    Clin Cancer Res; 2011 Feb 15; 17(4):731-41. PubMed ID: 21169242
    [Abstract] [Full Text] [Related]

  • 17. Inhibition of polo-like kinase 1 leads to the suppression of osteosarcoma cell growth in vitro and in vivo.
    Liu X, Choy E, Harmon D, Yang S, Yang C, Mankin H, Hornicek FJ, Duan Z.
    Anticancer Drugs; 2011 Jun 15; 22(5):444-53. PubMed ID: 21399492
    [Abstract] [Full Text] [Related]

  • 18. Effect of antisense RNA targeting polo-like kinase 1 on cell cycle and proliferation in A549 cells.
    Zhou Q, Bai M, Su Y.
    Chin Med J (Engl); 2004 Nov 15; 117(11):1642-9. PubMed ID: 15569479
    [Abstract] [Full Text] [Related]

  • 19. Hsa-let-7b inhibits cell proliferation by targeting PLK1 in HCC.
    He Z, Deng W, Jiang B, Liu S, Tang M, Liu Y, Zhang J.
    Gene; 2018 Oct 05; 673():46-55. PubMed ID: 29913237
    [Abstract] [Full Text] [Related]

  • 20. Plk1 depletion in nontransformed diploid cells activates the DNA-damage checkpoint.
    Lei M, Erikson RL.
    Oncogene; 2008 Jun 26; 27(28):3935-43. PubMed ID: 18297112
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.